Genor Biopharma Holdings (FRA:67N0) Research & Development: €21.21 Mil (TTM As of Jun. 2025)


FRA:67N0 Genor Biopharma Holdings Ltd FRA:67N0
22 GF Score
Price €0.34
! 1 Warning Sign
View Full Analysis

What is Genor Biopharma Holdings Research & Development?

Genor Biopharma Holdings FRA:67N0 +3.70% 22 Research & Development is €21.21 Mil as of Jun. 2025. GuruFocus rates FRA:67N0 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Genor Biopharma Holdings's Research & Development for the six months ended in Jun. 2025 was €9.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 was €21.21 Mil.

Genor Biopharma Holdings  (FRA:67N0) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Genor Biopharma Holdings Research & Development Related Terms

Genor Biopharma Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Genor Biopharma Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genor Biopharma Holdings Research & Development Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial 87.56 85.14 79.06 72.47 26.60

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.97 43.60 14.05 12.21 9.00
FRA:67N0
22GF Score
Genor Biopharma Holdings Ltd FRA:67N0
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genor Biopharma Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €21.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €21.21 Mil mean?
Genor Biopharma Holdings (FRA:67N0) has a Research & Development of €21.21 Mil as of Jun. 2025. Research and development expense is the total cost for research and development activities. View historical data on Genor Biopharma Holdings and its competitors.
Is Genor Biopharma Holdings' Research & Development too high?
Genor Biopharma Holdings' current Research & Development is €21.21 Mil. Overall, Genor Biopharma Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Genor Biopharma Holdings' Research & Development compare to VRTX and REGN?
Genor Biopharma Holdings' Research & Development of €21.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Genor Biopharma Holdings and its competitors. Genor Biopharma Holdings's current Research & Development is €21.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genor Biopharma Holdings stock overvalued right now?
Genor Biopharma Holdings (FRA:67N0) has a current Research & Development of €21.21 Mil. The current Research & Development is €21.21 Mil. Genor Biopharma Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Genor Biopharma Holdings (FRA:67N0), the current Research & Development is €21.21 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genor Biopharma Holdings Business Description

Address 690 Bibo Road, Room 501-02, Building 6, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
22GF Score

Get the complete analysis for FRA:67N0

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price